← Back to Home

Targeting MYC Cancer Through Transcriptional Condensates: Cancer Research UK Backs Dewpoint Drug’s Path to Human Trials

DPTX8743 aims to disrupt the molecular organization through which cancer cells activate genes. A new collaboration will support preclinical preparations and a first-in-human trial, but the evidence supporting this approach still comes from preclinical models.

By SURL BioNews

Stopping cancer cell growth sometimes requires first dismantling the way cells activate genes. MYC, a cancer driver that has long been difficult to target with drugs, now has a new therapeutic approach moving toward testing in humans: Cancer Research UK will support Dewpoint Therapeutics’ experimental small molecule DPTX8743 to test whether disrupting MYC-associated transcriptional condensates could become a treatment strategy.

The two organizations announced the collaboration on November 17. Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the preparatory studies required for a clinical trial application, as well as a first-in-human Phase 1/2a trial. The agreement provides resources and a team to take the drug toward clinical development; the announcement itself does not mean that trial enrollment has begun.

MYC helps regulate gene expression in cells, and its abnormal activity is associated with multiple cancers. The development strategy for DPTX8743 is to disrupt the transcriptional condensates that support MYC activity. These condensates can be understood as localized structures within cells that bring relevant molecules together to assist gene transcription; the drug targets this process rather than directly blocking the MYC protein itself.

According to announcements from Dewpoint and Cancer Research Horizons, DPTX8743 can disrupt these condensates, reduce MYC-driven gene expression and induce tumor cell death in preclinical models. However, the two announcements concern the same collaboration and do not represent two independent studies; neither provided complete model, dose and toxicity data sufficient to assess the magnitude of the effects.

The next stage of clinical development must therefore first address safety, then seek early evidence of whether this mechanism can have an effect in patients. The announcements list ovarian, esophageal, colorectal and pancreatic cancers as potential applications, but do not specify enrollment plans for each cancer type, patient selection criteria or when the trial will begin. This list cannot be treated as a confirmed indication strategy.

The collaboration also preserves flexibility for subsequent commercial development. Dewpoint retains all rights to DPTX8743 and can obtain licenses to research results and intellectual property generated through the collaboration; Cancer Research UK is eligible to receive subsequent milestone payments and royalties. Cancer Research Horizons will manage the commercial relationship between the parties. The announcements did not disclose specific financial amounts.

The significance of this development is that it gives a MYC treatment concept based on targeting condensates support to advance toward testing in humans. Critical clinical evidence is still needed to bridge the gap between tumor cell death in models and whether patients can safely benefit; Phase 1/2a development will be the starting point for assessing that gap.

References

  1. Dewpoint Therapeutics
  2. Cancer Research Horizons